Monoclonal antibodies and small molecules? Feh! Archemix is focused on aptamers, a type of synthetic oligonucleotide that the drug discovery company believes will trump those other cutting edge biotech tools in treating acute and chronic diseases. Aptamers bind to molecular targets much like antibodies but are more easily reproduced. It has R&D programs for potential treatments for cancers, rheumatoid arthritis, and multiple sclerosis. The company has partnered with larger firms including Merck Serono, GlaxoSmithKline, and Elan Pharmaceuticals.